A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma, Non-Hodgkin's

In brief

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop

Key facts

Study ID
NCT00413036
Run by
Celgene
People needed
217
Starts
2006-06-01
Expected to finish
2011-05-01
Last updated by the study team
2017-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.